US2021100882A1PendingUtilityA1

Autoimmune antigens and cancer

56
Assignee: UNIV JOHNS HOPKINSPriority: Dec 4, 2013Filed: Oct 22, 2020Published: Apr 8, 2021
Est. expiryDec 4, 2033(~7.3 yrs left)· nominal 20-yr term from priority
Inventors:Erika Lynn DarrahAmi A. ShahLivia Casciola-RosenAntony RosenChristine JosephBert VogelsteinKenneth W. KinzlerNickolas Papadopoulos
A61K 39/0008A61K 2039/585A61P 35/00A61K 38/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Autoimmune diseases are thought to be initiated by exposures to foreign antigens that cross-react with endogenous molecules. Analyses of peripheral blood lymphocytes and serum suggested that mutations in autoimmune antigen targets sparked cellular immunity and cross-reactive humoral immune responses. Acquired immunity to autoimmune antigens can help control naturally occurring cancers.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method, comprising:
 administering to a patient having a cancer a peptide of 10-40 contiguous amino acid residues of a human, autoimmune antigen, wherein the peptide binds with high affinity to an HLA protein of the patient, wherein the peptide comprises a variant residue relative to the wild-type antigen.   
     
     
         2 . The method of  claim 1  wherein prior to the step of administering the patient sample is tested to ascertain the patient's HLA type. 
     
     
         3 . The method of  claim 1  wherein the antigen is TOP1. 
     
     
         4 . The method of  claim 1  wherein the antigen is CENPB. 
     
     
         5 . The method of  claim 1  wherein the antigen is Mi-2. 
     
     
         6 . The method of  claim 1  wherein a full-length version of the antigen is co-administered with the peptide. 
     
     
         7 . The method of  claim 1  wherein a full-length, wild-type version of the antigen is co-administered with the peptide. 
     
     
         8 . The method of  claim 1  wherein a full-length, mutant version of the antigen is co-administered with the peptide, wherein the antigen and the peptide comprise the variant residue. 
     
     
         9 . The method of  claim 1  wherein the cancer is selected from the group consisting of breast, lung, ovarian, colorectal, and B cell lymphoma. 
     
     
         10 . The method of  claim 1  wherein the peptide comprises 10-30 contiguous residues of the antigen. 
     
     
         11 . The method of  claim 1  wherein the peptide comprises 10-20 contiguous residues of the antigen. 
     
     
         12 . The method of  claim 1  wherein the peptide comprises 13-18 contiguous residues of the antigen. 
     
     
         13 . The method of  claim 1  wherein the antigen is selected from the group consisting of CENP A, CENP B, CENP C, topoisomerase-1, nucleophosmin, fibrillarin, UBF, RPP30, RPP40, RPB1, RPB2, P80 coilin, UBF, nucleolin, CEP250, PCM1, TRIM21, components of the exosome complex, PARP1, Histone H1, Histone H2, Histone H3, Histone H4, SmB, SmD, SmG, U1-70k, Ro52, Ro60, La, Ribosomal P2, Ribosomal P0, Ribosomal P1, Ki-67, PCNA, Defensin beta, Defensin a-4, Defensin a-3, Defensin a-1, LL37, ASF/SF2, SR proteins, IFI-16, AQP4, M3R, Fodrin alpha, Golgin-160, GM130, NuMA, Giantin, RBBP7, CHD4, RBBP4 (NuRD), MBD3, SWI/SNF-related, CHD3, HDAC1, PMS1, PMS2, DNA-PK, RNA helicase DHX15, XRCC4, TIF-1g/TRIM 24, TIF-1b, Ku-70, Ku-86, NXP2/MORC3, HMGCR, PUF-60, FUBP1, PM SCL 100k, PM SCL 40k, Histidyl tRNA synthetase, Alanyl tRNA synthetase, Lysyl tRNA synthetase, Threonyl tRNA synthetase, Asparaginyl tRNA synthetase, MDA5, SRP54, SRP 72, SRP19, PALLD, SAE1, SAE2, Pr3, MPO, LAMP2, Vimentin, and PAD4. 
     
     
         14 . An isolated peptide of 10-40 contiguous amino acid residues of a human, autoimmune antigen, wherein the peptide binds with high affinity to a human HLA protein, wherein the peptide comprises a variant residue relative to the wild-type antigen. 
     
     
         15 . The isolated peptide of  claim 14  wherein the antigen is selected from the group consisting of CENP A, CENP B, CENP C, topoisomerase-1, nucleophosmin, fibrillarin, UBF, RPP30, RPP40, RPB1, RPB2, P80 coilin, UBF, nucleolin, CEP250, PCM1, TRIM21, components of the exosome complex, PARP1, Histone H1, Histone H2, Histone H3, Histone H4, SmB, SmD, SmG, U1-70k, Ro52, Ro60, La, Ribosomal P2, Ribosomal P0, Ribosomal P1, Ki-67, PCNA, Defensin beta, Defensin a-4, Defensin a-3, Defensin a-1, LL37, ASF/SF2, SR proteins, IFI-16, AQP4, M3R, Fodrin alpha, Golgin-160, GM130, NuMA, Giantin, RBBP7, CHD4, RBBP4 (NuRD), MBD3, SWI/SNF-related, CHD3, HDAC1, PMS1, PMS2, DNA-PK, RNA helicase DHX15, XRCC4, TIF-lg/TRIM 24, TIF-1b, Ku-70, Ku-86, NXP2/MORC3, HMGCR, PUF-60, FUBP1, PM SCL 100k, PM SCL 40k, Histidyl tRNA synthetase, Alanyl tRNA synthetase, Lysyl tRNA synthetase, Threonyl tRNA synthetase, Asparaginyl tRNA synthetase, MDA5, SRP54, SRP 72, SRP19, PALLD, SAE1, SAE2, Pr3, MPO, LAMP2, Vimentin, and PAD4. 
     
     
         16 . The isolated peptide of  claim 14  wherein the peptide comprises 10-30 contiguous residues of the antigen. 
     
     
         17 . The isolated peptide of  claim 14  wherein the peptide comprises 10-20 contiguous residues of the antigen. 
     
     
         18 . The isolated peptide of  claim 14  wherein the peptide comprises 13-18 contiguous residues of the antigen. 
     
     
         19 . The isolated peptide of  claim 14  which is in admixture with a full-length version of the antigen. 
     
     
         20 . The isolated peptide of  claim 19  wherein the full-length version of the antigen is a wild-type antigen.

Join the waitlist — get patent alerts

Track US2021100882A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.